The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | The importance of early diagnosis in AL amyloidosis to improve outcomes for patients
In this video, Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, discusses the importance of early diagnosis in light chain (AL) amyloidosis, which is crucial to improve outcomes for patients. Diagnosing patients at a later stage in their disease can limit the treatment options available, and Dr Nuvolone highlights the value of early screening and monitoring of various biomarkers. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
